dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
176 |
4. Check minimum number of eventsNone |
176 |
5. Include endpointsNone |
176 |
6. Filter based on genotype QC (FinnGen only) |
176 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Alia dermatomyositis
Similar endpoints
↥List of similar endpoints to
Other dermatomyositis
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 994 | 672 | 312 |
| Only index persons | 759 | 525 | 234 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.13 | 53.64 | 54.89 |
| Only index persons | 51.33 | 51.38 | 51.23 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 176 | 123 | 53 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.02 |
| Median age at first event (years) | 53.89 | 52.72 | 56.63 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 163
- Matched controls
- 1629
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
205.8
151
*
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
73.6
65
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
30.6
68.5
99
78
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
20.5
44.8
71
59
P01BA02
ATC
hydroxychloroquine; oral
19.4
41.2
66
55
M33.2
ICD-10 Finland
Polymyositis
+∞
40.3
37
*
L04AX01
ATC
azathioprine; systemic
26.7
37.1
52
28
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
16.7
34.5
58
52
H02AB06
ATC
prednisolone; systemic
9.0
33.2
133
536
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.1
29.7
112
385
NXL00
NOMESCO Finland
Biopsy of muscle
+∞
23.5
22
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
23.5
22
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.9
19.9
36
35
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
9.0
17.7
39
55
L04AA06
ATC
mycophenolic acid; systemic
36.0
17.5
22
7
M05BA04
ATC
alendronic acid; oral
8.0
17.5
42
68
L04AD01
ATC
ciclosporin; systemic
23.2
17.0
24
12
M60.9
ICD-10 Finland
Myositis, unspecified
+∞
17.0
16
*
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
17.0
16
*
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
13.8
16.3
28
24
G72.9
ICD-10 Finland
Myopathy, unspecified
62.7
15.1
17
*
H02AB07
ATC
prednisone; oral
5.1
14.9
53
141
71600
ICD-8 Finland
Polymyositis and dermatomyositis, Dermatomyositis
+∞
14.8
14
*
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
+∞
13.7
13
*
7103B
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS ADULTORUM]
+∞
13.7
13
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
10.3
12.8
25
28
M05BA07
ATC
risedronic acid; oral
11.9
12.2
22
21
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.6
11.8
67
263
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
11.6
11
*
M33
ICD-10 Finland
Dermatopolymyositis
+∞
11.6
11
*
L04AA01
ATC
[U] ciclosporin; systemic
22.0
11.4
16
8
XQ848
NOMESCO Finland
Dermatological photography
17.1
11.1
17
11
D07AB08
ATC
desonide; topical
5.2
10.9
35
81
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
64.3
10.8
12
*
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
+∞
10.5
10
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.7
10.2
26
45
ZX120
NOMESCO Finland
Intravenous
4.9
10.1
34
83
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
9.9
88
464
D07AC01
ATC
betamethasone; topical
3.1
9.9
73
339
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
9.5
9
*
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
9.5
9
*
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
9.5
9
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.5
9.0
45
158
R4110
NOMESCO Finland
Physiotherapy
3.0
8.9
65
298
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
12.6
8.8
15
13
R4120
NOMESCO Finland
Occupational therapy
6.2
8.7
23
42
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.6
8.7
25
51
L93.0
ICD-10 Finland
Discoid lupus erythematosus
+∞
8.4
8
*
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
35.3
8.2
10
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
35.3
8.2
10
*
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
11.6
8.0
14
13
TPH04
NOMESCO Finland
Cathetrisation of vein
3.3
7.7
42
156
D07AC13
ATC
mometasone; topical
2.8
7.6
59
276
M60.8
ICD-10 Finland
Other myositis
83.7
7.5
8
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.4
6.7
24
62
E0000UV
ATC
NA
2.4
6.5
74
418
M81.4
ICD-10 Finland
Drug-induced osteoporosis
72.5
6.5
7
*
D07AB02
ATC
hydrocortisone butyrate; topical
2.6
6.4
56
276
C03CA01
ATC
furosemide; systemic
2.6
6.4
54
261
XG410
NOMESCO Finland
Flow-volume spirometry
6.8
6.3
15
24
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
6.8
6.3
15
24
318
Kela drug reimbursment
Teriparatide
+∞
6.3
6
*
H05AA02
ATC
teriparatide; parenteral
+∞
6.3
6
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.3
6.2
31
107
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
6.2
44
192
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.7
6.2
20
47
R50.9
ICD-10 Finland
Fever, unspecified
3.3
6.2
31
108
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
6.2
31
108
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
7.7
6.1
13
18
E000001
ATC
NA
2.8
6.0
41
175
JN4BD
NOMESCO Finland
Extensive body CT
3.3
6.0
30
104
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
40
40
12.65
36.79
1.5
1.1
0.2
0.2
g/l
2.44
40
40
40
43
11.74
34.97
1.5
1.1
1.1
1.3
g/l
1.50
40
43
31
38
9.69
24.29
2.0
1.4
—
—
—
0
0
18
10
19.94
22.39
1.3
1.0
—
—
—
0
0
18
10
19.94
22.39
1.3
1.0
—
—
—
0
0
18
11
18.11
21.41
1.3
1.0
—
—
—
0
0
18
11
18.11
21.41
1.3
1.0
—
—
—
0
0
18
11
18.11
21.41
1.3
1.0
—
—
—
0
0
142
798
5.03
18.12
19.7
9.5
4.1
4.1
e9/l
0.10
137
705
15
10
16.30
16.95
1.1
1.1
—
—
—
0
0
20
37
5.97
10.67
1.2
1.4
550.1
0.1
iu/ml
—
6
5
20
42
5.24
9.32
1.4
2.4
37.5
38.1
g/l
0.14
20
37
18
35
5.61
9.09
3.9
2.3
—
—
—
0
0
109
668
2.66
8.99
9.4
6.6
1.2
1.2
mmol/l
0.09
98
562
21
48
4.83
8.88
1.3
2.2
3.1
2.9
g/l
0.47
21
40
14
22
6.83
8.67
5.4
2.6
62.4
62.3
%
0.01
14
22
21
52
4.45
8.06
1.3
2.1
—
—
—
0
0
21
52
4.45
8.06
1.3
2.1
7.2
7.2
g/l
0.03
21
41
21
52
4.45
8.06
1.3
2.1
3.6
3.5
g/l
0.10
21
38
13
21
6.60
7.83
5.1
2.0
4.3
6.0
e9/l
1.12
13
21
50
225
2.71
7.54
5.4
3.4
0.8
0.8
mmol/l
0.32
45
213
72
392
2.42
7.25
4.3
2.8
0.2
0.5
e6/l
1.49
54
287
105
695
2.27
6.47
5.5
3.7
0.0
0.0
estimate
0.00
17
141
103
680
2.24
6.34
5.6
3.7
0.0
0.0
estimate
0.00
18
143
81
488
2.22
6.23
4.9
2.9
—
—
—
0
0
103
688
2.20
6.06
7.8
5.0
0.0
0.0
estimate
0.00
18
143
59
315
2.31
6.03
2.5
2.0
3.9
3.2
mg/l
0.97
54
268
16
41
4.19
5.86
1.1
1.1
—
—
—
0
0
91
586
2.14
5.80
3.2
2.2
75.1
77.4
nmol/l
0.36
85
518
46
229
2.37
5.46
3.4
2.5
0.6
0.8
e6/l
0.74
31
125
11
22
5.27
5.33
1.2
1.4
—
—
—
0
0
10
20
5.24
4.84
2.2
1.6
—
—
—
0
0
32
143
2.51
4.76
9.7
7.5
5.4
5.0
kpa
0.95
27
137
32
143
2.51
4.76
9.7
7.5
11.2
12.4
kpa
0.65
27
137
40
206
2.22
4.32
2.1
1.8
—
—
—
0
0
8
9
9.24
4.32
2.6
2.2
—
—
—
0
0
41
217
2.16
4.13
3.7
2.7
3.4
2.9
e6/l
0.17
26
115
30
144
2.31
3.81
10.2
7.5
1.8
1.2
mmol/l
0.32
24
111
9
16
5.86
3.71
2.1
1.3
—
—
—
0
0
7
9
8.04
3.59
2.7
1.3
—
—
—
0
0
6
6
10.29
3.52
1.0
1.2
94.5
84.2
iu/ml
—
6
6
58
372
1.83
3.33
4.4
3.2
1025.2
1447.9
ng/l
0.66
53
319
8
15
5.53
3.23
1.0
1.2
—
—
—
0
0
7
11
6.57
3.21
1.0
1.1
—
—
—
0
0
55
351
1.82
3.20
1.3
1.2
0.6
1.7
u/ml
1.11
11
104
9
20
4.68
3.16
1.2
1.4
—
—
—
0
0
9
20
4.68
3.16
1.2
1.4
—
—
—
0
0
10
29
3.60
3.09
2.2
1.7
—
—
—
0
0
7
12
6.02
3.05
1.0
1.3
—
—
—
0
0
9
21
4.46
3.04
1.0
1.5
—
—
—
0
0
5
5
10.24
2.99
4.0
1.6
58.6
82.8
ug/l
—
5
5
8
17
4.88
2.95
2.5
1.6
—
—
—
0
0
10
31
3.36
2.82
2.2
1.7
—
—
—
0
0
27
142
2.06
2.74
2.0
1.7
—
—
—
0
0
7
15
4.81
2.62
1.3
1.6
—
—
—
0
0
29
162
1.95
2.50
2.2
4.5
3.6
76.9
ug/l
0.86
23
134
128
1441
0.59
2.36
4.9
4.9
2.9
2.8
mmol/l
0.94
122
1320
7
18
4.00
2.27
1.3
1.6
—
—
—
0
0
5
9
5.68
2.23
1.4
1.1
—
—
—
0
0
39
252
1.70
2.11
1.2
1.2
31.1
42.4
iu/ml
—
9
84
122
1380
0.62
2.11
4.2
4.4
5.6
5.9
mmol/l
2.30
117
1262
8
26
3.17
2.04
2.1
1.7
—
—
—
0
0
24
136
1.89
1.99
3.0
2.3
0.2
0.2
g/l
0.70
24
126
7
21
3.43
1.98
1.6
3.0
31.7
86.7
u/ml
—
7
21
8
27
3.05
1.96
1.8
1.7
—
—
—
0
0
127
1416
0.63
1.92
4.5
4.4
4.8
4.7
mmol/l
0.52
121
1301
7
22
3.27
1.90
3.6
1.2
—
—
—
0
0
50
357
1.56
1.82
3.9
2.6
330.4
8963.3
umol/l
2.48
44
305
70
538
1.50
1.81
5.9
3.7
—
—
—
0
0
5
13
3.92
1.72
1.2
2.3
—
—
—
0
0
5
13
3.92
1.72
1.2
2.3
—
—
—
0
0
5
13
3.92
1.72
1.2
2.3
—
—
—
0
0
127
1406
0.65
1.68
4.5
4.3
1.5
1.5
mmol/l
0.69
121
1285
8
31
2.65
1.68
1.1
1.0
—
—
—
0
0
38
259
1.60
1.67
1.8
1.6
910.5
1272.2
nmol/l
2.28
31
195
11
49
2.33
1.67
1.4
1.3
—
—
—
0
0
12
57
2.19
1.59
1.1
1.4
—
—
—
0
0
12
57
2.19
1.59
4.8
3.4
39.1
45.0
%
0.33
12
57
10
44
2.35
1.56
2.0
1.8
—
—
—
0
0
8
33
2.49
1.56
2.1
1.3
—
—
—
0
0
23
140
1.74
1.54
2.2
1.7
—
—
—
0
0
5
15
3.40
1.53
1.2
2.0
—
—
—
0
0
43
308
1.52
1.53
1.7
1.8
1.3
1.2
mg/l
0.15
31
242
5
17
3.00
1.37
1.2
1.9
—
—
—
0
0
26
170
1.62
1.36
13.4
6.4
103.9
104.0
mmol/l
0.04
26
164
50
380
1.44
1.32
6.7
3.9
0.0
0.0
estimate
0.00
17
142
12
62
2.00
1.31
2.2
2.5
45.8
42.4
u/l
0.30
12
56
16
92
1.81
1.30
1.4
1.6
—
—
—
0
0
123
1350
0.70
1.27
4.1
3.9
1.3
1.3
mmol/l
0.56
118
1225
5
19
2.68
1.22
1.6
1.5
—
—
—
0
0
30
209
1.52
1.21
2.6
1.7
34.0
29.5
s
0.95
30
203
34
244
1.49
1.20
1.2
1.2
8.8
20.2
u/ml
—
9
86
10
50
2.06
1.19
2.3
2.1
—
—
—
0
0
5
20
2.54
1.16
1.6
1.1
—
—
—
0
0
11
62
1.83
0.96
1.8
1.3
—
—
—
0
0
7
37
1.93
0.95
1.1
1.1
—
17.0
—
0
6
13
78
1.72
0.94
1.0
1.0
—
—
—
0
0
13
78
1.72
0.94
1.2
1.7
—
—
—
0
0
34
258
1.39
0.90
1.6
1.5
—
—
—
0
0
15
225
0.64
0.89
3.0
4.5
22.4
21.6
%
—
8
114
8
138
0.56
0.87
1.4
1.6
—
—
—
0
0
78
677
1.27
0.82
5.0
4.0
—
—
—
0
0
104
941
1.26
0.75
3.6
3.0
53.9
46.2
u/l
0.47
99
888
152
1448
1.36
0.68
29.3
13.0
20.9
23.1
mg/l
0.38
136
1122
8
50
1.63
0.62
1.3
1.6
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
0
22
0.00
0.59
0.0
1.3
—
—
—
0
0
124
1314
0.81
0.58
5.9
5.5
40.5
39.6
mmol/mol
0.48
119
1218
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
6
35
1.74
0.58
1.0
1.7
—
—
—
0
0
60
525
1.22
0.56
3.5
3.6
133.6
30.1
ng/l
0.97
49
348
12
83
1.48
0.53
14.8
5.7
26.8
25.0
mmol/l
0.67
12
83
84
913
0.85
0.48
3.0
3.1
—
—
—
0
0
10
68
1.50
0.48
3.1
2.3
1.3
1.1
%
—
10
68
7
51
1.39
0.44
1.3
1.1
—
—
—
0
0
13
172
0.74
0.43
11.0
6.7
—
—
—
0
0
10
70
1.45
0.42
2.6
3.5
2.0
1.2
mmol/l
—
10
52
0
15
0.00
0.41
0.0
2.0
—
2.2
—
0
5
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
5
34
1.48
0.40
4.2
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
10.7
—
0
6
5
35
1.44
0.39
1.8
2.7
18.2
36.3
u/ml
—
5
35
5
35
1.44
0.39
1.0
1.6
—
—
—
0
0
13
168
0.76
0.37
2.4
2.8
0.7
0.7
ug/l
—
8
111
17
136
1.28
0.35
6.5
3.8
—
—
—
0
0
39
344
1.17
0.33
2.2
2.4
—
—
—
0
0
61
564
1.12
0.27
2.3
1.9
90.6
96.9
pmol/l
0.63
32
277
106
1101
0.91
0.22
5.5
4.2
14.9
14.7
pmol/l
0.18
98
996
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
41.0
—
0
7
0
12
0.00
0.21
0.0
1.0
—
452.7
—
0
7
36
394
0.89
0.21
1.7
1.6
1.5
1.4
mmol/l
0.33
30
327
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
50
1.21
0.20
1.2
1.1
—
—
—
0
0
14
119
1.19
0.18
3.4
2.2
88.6
64.0
ml/min/173m2
—
5
48
26
284
0.90
0.14
3.3
5.0
2.3
2.0
ug/l
0.16
21
253
132
1346
0.92
0.14
24.3
12.9
88.5
81.8
ml/min/173m2
2.18
119
1088
6
54
1.11
0.09
1.5
1.6
—
—
—
0
0
8
73
1.10
0.07
1.5
1.7
—
—
—
0
0
9
88
1.02
0.07
1.2
1.3
—
—
—
0
0
17
158
1.08
0.06
2.1
2.0
—
—
—
0
0
130
1315
0.96
0.06
5.8
4.9
1.8
1.9
mu/l
0.63
121
1193
153
1518
1.06
0.05
31.6
15.8
71.9
74.3
umol/l
0.27
153
1518
11
101
1.10
0.04
1.5
1.3
60.3
133.1
iu/ml
—
5
39
130
1310
0.97
0.03
31.3
14.3
39.2
39.7
%
0.28
97
968
13
138
0.94
0.02
2.2
1.8
—
—
—
0
0
27
267
1.01
0.00
1.5
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
2.6
—
—
—
0
0
5
51
0.98
0.00
1.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
17.2
—
0
5
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
204.1
—
0
9
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_DERMATOMYOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 2.82 [2.11, 3.76] | < 0.001 |
| Birth year | 1.001 [0.99, 1.01] | 0.762 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 411 females with M13_DERMATOMYOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 3.103 [2.28, 4.22] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 201 males with M13_DERMATOMYOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_DERMATOMYOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.228% | 0.515% |
| 5 | 1.755% | 3.094% |
| 10 | 4.592% | 7.916% |
| 15 | 9.262% | 14.67% |
| 20 | 16.456% | 24.478% |
Relationships between endpoints
↥Index endpoint: M13_DERMATOMYOTH – Other dermatomyositis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data